Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

ATOMXETINE HYROCHLORIDE

×

Overview

What is STRATTERA?

STRATTERA (atomoxetine HCl) is a selective norepinephrine reuptake inhibitor. Atomoxetine HCl is the (-) isomer as determined by x–ray diffraction. The chemical designation is (-)--Methyl-3-phenyl-3-(-tolyloxy)-propylamine hydrochloride. The molecular formula is CHNO•HCl, which corresponds to a molecular weight of 291.82. The chemical structure is:

Atomoxetine HCl is a white to practically white solid, which has a solubility of 27.8 mg/mL in water.

STRATTERA capsules are intended for oral administration only.

Each capsule contains atomoxetine HCl equivalent to 10, 18, 25, 40, 60, 80, or 100 mg of atomoxetine. The capsules also contain pregelatinized starch and dimethicone. The capsule shells contain gelatin, sodium lauryl sulfate, and other inactive ingredients. The capsule shells also contain one or more of the following:

FD&C Blue No. 2, synthetic yellow iron oxide, titanium dioxide, red iron oxide. The capsules are imprinted with edible black ink.



What does STRATTERA look like?



What are the available doses of STRATTERA?

Each capsule contains atomoxetine HCl equivalent to 10, 18, 25, 40, 60, 80, or 100 mg of atomoxetine.

What should I talk to my health care provider before I take STRATTERA?

How should I use STRATTERA?

STRATTERA is indicated for the treatment of Attention–Deficit/Hyperactivity Disorder (ADHD).

The efficacy of STRATTERA Capsules was established in seven clinical trials in outpatients with ADHD: four 6 to 9-week trials in pediatric patients (ages 6 to 18), two 10-week trial in adults, and one maintenance trial in pediatrics (ages 6 to 15)

Dosing of children and adolescents up to 70 kg body weight

The total daily dose in children and adolescents should not exceed 1.4 mg/kg or 100 mg, whichever is less.

Dosing of children and adolescents over 70 kg body weight and adults

The maximum recommended total daily dose in children and adolescents over 70 kg and adults is 100 mg.


What interacts with STRATTERA?

Sorry No Records found


What are the warnings of STRATTERA?

Sorry No Records found


What are the precautions of STRATTERA?

Sorry No Records found


What are the side effects of STRATTERA?

Sorry No records found


What should I look out for while using STRATTERA?

Hypersensitivity to atomoxetine or other constituents of product.

STRATTERA use within 2 weeks after discontinuing MAOI or other drugs that affect brain monoamine concentrations.

Narrow Angle Glaucoma.

STRATTERA (atomoxetine) increased the risk of suicidal ideation in short–term studies in children or adolescents with Attention–Deficit/Hyperactivity Disorder (ADHD). Anyone considering the use of STRATTERA in a child or adolescent must balance this risk with the clinical need. Co-morbidities occurring with ADHD may be associated with an increase in the risk of suicidal ideation and/or behavior. Patients who are started on therapy should be monitored closely for suicidality (suicidal thinking and behavior), clinical worsening, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. STRATTERA is approved for ADHD in pediatric and adult patients. STRATTERA is not approved for major depressive disorder.

Pooled analyses of short–term (6 to 18 weeks) placebo–controlled trials of STRATTERA in children and adolescents (a total of 12 trials involving over 2200 patients, including 11 trials in ADHD and 1 trial in enuresis) have revealed a greater risk of suicidal ideation early during treatment in those receiving STRATTERA compared to placebo. The average risk of suicidal ideation in patients receiving STRATTERA was 0.4% (5/1357 patients), compared to none in placebo–treated patients (851 patients). No suicides occurred in these trials


What might happen if I take too much STRATTERA?


How should I store and handle STRATTERA?

Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].Pravastatin sodium tablets 10 mg tablets: 20 mg tablets: 40 mg tablets: 80 mg tablets: They are supplied by as follows:Pravastatin sodium tablets 10 mg tablets: 20 mg tablets: 40 mg tablets: 80 mg tablets: They are supplied by as follows:Pravastatin sodium tablets 10 mg tablets: 20 mg tablets: 40 mg tablets: 80 mg tablets: They are supplied by as follows:Pravastatin sodium tablets 10 mg tablets: 20 mg tablets: 40 mg tablets: 80 mg tablets: They are supplied by as follows:Pravastatin sodium tablets 10 mg tablets: 20 mg tablets: 40 mg tablets: 80 mg tablets: They are supplied by as follows:Pravastatin sodium tablets 10 mg tablets: 20 mg tablets: 40 mg tablets: 80 mg tablets: They are supplied by as follows: